anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participant will receive one subcutaneous dose of Denosumab within 2 weeks after confirmation of bone marrow engraftment. The dose of treatment will be escalated between participants. Denosumab is supposed to be effective for several months (4 to 6 months). The biologic activity of Denosumab will be followed by the measure in the blood of a biomarker of bone destruction called CTX. This biomarker is supposed to decrease after Denosumab infusion, reflecting the blockade of bone destruction by the treatment. Bone density will be assessed by a radiologic test named DXA which a standard test. All blood and radiologic tests mandated by the study will be done at the same time as standard follow-up after bone marrow transplant. Thus, participants will not have extra visits at the outpatient clinic, or extra blood punctures, for the specific purpose of the study. Participants will be followed for 36 months after bone marrow transplantation.For experiencing graft versus host disease, a second dose of Denosumab will be allowed, followed by subsequent doses evry 4 to 6 months till a maximum of 4 doses within 24months after bone marrow transplantation.
The current proposed crossover study is a single center, open-label clinical trial in patients who have severe obesity (defined by body mass index greater than or equal to 40 kg/m2) and are recovering from anesthesia. The primary aim is to describe the difference cardiopulmonary function between two settings for continuous positive airway pressure (CPAP), using electrical impedance tomography (EIT), transthoracic echocardiography, and esophageal pressure monitoring to measure response. The secondary aim is to determine whether the location of adipose tissue modifies responses to CPAP settings.

The study protocol consists of placing an esophageal catheter to monitor intrathoracic pressure in the operating room when the participant is under anesthesia. In the post-anesthesia care unit, participants will receive two CPAP settings, in random order, for 20 minutes each. One setting is a recruitment maneuver and CPAP set to the level of end-expiratory pressure (intrathoracic pressure). Another setting is a CPAP set to home levels (if known) or 8-10 cmH20 if not on home CPAP. There will be a 10 minute washout period between interventions. Investigators will monitor airway and esophageal pressure, ventilation with electrical impedance tomography, right heart function with transthoracic echocardiography, and abdominal muscle contraction with ultrasound. Waist and hip circumference will be measured prior to CPAP.
Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
Obesity is the second leading cause of death in the U.S. The treatment of obesity and its related comorbidities, including cardiovascular disease and diabetes, exceeds $150 billion annually. "Morbidly" or "severely" obese patients - defined by a body mass index \[BMI\] of \>35 kg/m2 or greater - are especially high risk for serious complications due to the metabolic and physiologic derangements that occur with severe obesity. Within the Veterans Health Administration (VA) system, nearly 600,000 patients are severely obese. These Veterans exert significant costs on the VA system, experience poorer quality of life, and have shortened lifespans. Bariatric surgery is the most effective treatment for severe obesity for weight loss, comorbidity resolution, and quality of life. Bariatric surgery is supported as a treatment option by many national societies, including those representing primary care and endocrinology. However, less than 1% of Veterans who qualify for bariatric surgery undergo it. Reasons for low utilization are unclear, although the investigators' preliminary research suggests that there are various patient, provider and system level barriers to severe obesity care. The goal of this study is to pilot-test an educational video that aligns patient preferences with treatment options to optimize the care that severely obese Veterans receive.
Myocardial infarction (MI) is an extremely severe cardiovascular disease, which ranks as the leading cause of sudden death worldwide. Studies have proved that cardiac injury following MI can cause cardiomyocyte apoptosis and myocardial fibrosis. Bilobalide (Bilo) from Ginkgo biloba leaves have been widely reported to possess excellent cardioprotective effects. However, concrete roles of Bilo in MI have not been investigated yet. We here designed both in vitro and in vivo experiments to explore the effects of Bilo on MI-induced cardiac injury and the underlying mechanisms of its action. We conducted in vitro experiments using oxygen-glucose deprivation (OGD)-treated H9c2 cells. Cell apoptosis in H9c2 cells was assessed by conducting flow cytometry assay and evaluating apoptosis-related proteins with western blotting. MI mouse model was established by performing left anterior descending artery (LAD) ligation. Cardiac function of MI mice was determined by assessing ejection fraction (EF), fractional shortening (FS), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD). Histological changes were analyzed, infarct size and myocardial fibrosis were measured by hematoxylin and eosin (H&E) and Masson staining in cardiac tissues from the mice. The apoptosis of cardiomyocytes in MI mice was assessed by TUNEL staining. Western blotting was applied to detect the effect of Bilo on c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinases (p38 MAPK) signaling both in vitro and in vivo. Bilo inhibited OGD-induced cell apoptosis and lactate dehydrogenase (LDH) release in H9c2 cells. The protein levels of p-JNK and p-p38 were significantly downregulated by Bilo treatment. SB20358 (inhibitor of p38) and SP600125 (inhibitor of JNK) suppressed OGD-induced cell apoptosis as Bilo did. In MI mouse model, Bilo improved the cardiac function and significantly reduced the infarct size and myocardial fibrosis. Bilo inhibited MI-induced cardiomyocytes apoptosis in mice. Bilo suppressed the protein levels of p-JNK and p-p38 in cardiac tissues from MI mice. Bilo alleviated OGD-induced cell apoptosis in H9c2 cells and suppressed MI-induced cardiomyocyte apoptosis and myocardial fibrosis in mice via the inactivation of JNK/p38 MAPK signaling pathways. Thus, Bilo may be an effective anti-MI agent.
Prior to scrubbing surgeon infiltrates the thought incision area with ropivacaine 3,75/ml (1mg/kg). Perioperatively after removal of the tumor follows the deep infiltration of the wound with ropivacaine 3,75mg/ml (2mg/kg).
OBJECTIVES: Human papillomavirus (HPV)-independent vulvar intraepithelial neoplasia (VIN) is a rare yet aggressive precursor lesion of vulvar cancer. Our objectives were to estimate its long-term incidence, the risk of recurrent disease and progression to vulvar cancer, and risk factors thereof.
MATERIALS AND METHODS: Patients with HPV-independent VIN between 1991 and 2019 in a selected region were identified from the Dutch Nationwide Pathology Databank (Palga). Data were collected from the pathology reports. Crude and European age-standardized incidence rates were calculated for 10-year periods. Kaplan-Meier analyses were performed to determine the cumulative recurrence and cancer incidence, followed by Cox regression analyses to identify associated risk factors.
RESULTS: A total of 114 patients were diagnosed with solitary HPV-independent VIN without prior or concurrent vulvar cancer. The European age-standardized incidence rate increased from 0.09 to 0.69 per 100,000 women-years between 1991-2010 and 2011-2019. A cumulative recurrence and cancer incidence of 29% and 46% were found after 8 and 13 years of follow-up, respectively. Nonradical surgery was identified as the only independent risk factor for recurrent HPV-independent VIN. Risk factors associated with progression to cancer were increasing age and a mutant p53 immunohistochemical staining pattern.
CONCLUSIONS: The incidence of detected HPV-independent VIN has substantially increased the last decade and the subsequent recurrence and vulvar cancer risks are high. Although HPV-independent VIN may present as a wide morphologic spectrum, surgical treatment should aim for negative resection margins followed by close surveillance, especially for p53 mutant lesions.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of being rapidly dissolved in an oral cavity and the like, having practically durable hardness and little in moisture absorbability by dissolving and/or dispersing a medicine in the aqueous solution of a specific saccharide as an excipient and subsequently lyophilizing the obtained solution or dispersion. SOLUTION: This preparation is obtained by dissolving and/or dispersing (A) a medicine (e.g. a medicine for central nervous systems, such as a sedative hypnotic, a medicine for peripheral nervous systems, such as an autonomic medicine, a medicine for circulatory organs, such as a cardiotonicum) in (B) the aqueous solution of a saccharide (preferably trehalose, mannitol, dextrin), and subsequently lyophilizing the obtained solution or dispersion. The component B is preferably used, after dissolved in water in an amount of 10-30 wt.%. The preparation preferably further contain a dispersant such as alpha-starch or methyl cellulose in an amount of <=3 wt.% based on the suspension.  The preparation is prepared e.g. by charging the suspension composition comprising the component A and the aqueous solution of the component B into a preparation template and subsequently lyophilizing the molded product.
Pharmaceutical preparations for topical or local administration of drugs directly to the skin for treatment of disorders of the subcutaneous fatty ti ssue, in particular in cases of cellulite, are disclosed herein. In a prefer red embodiment, the drug is danazol or gastrinone. In another embodiment, th e drug is danazol in combination with an aromatase inhibitor or an estrogen compound. The preferred formulations contain drugs in the form of micro or n anoparticles, which may be formed of drug alone or in combination with an ex cipient or carrier. The excipient or carrier may modify the release rates or enhance absorption into the affected area. The drug formulation may be in t he form of a cream, lotion, ointment, gel or emulsion, solution or foam.</SD OAB>
Macrophages are phagocytic cells with important physiological functions, including the digestion of cellular debris, foreign substances, and microbes, as well as tissue development and homeostasis. The tumor microenvironment (TME) shapes the aggressiveness of cancer, and the biological and cellular interactions in this complicated space can determine carcinogenesis. TME can determine the progression, biological behavior, and therapy resistance of human cancers. The macrophages are among the most abundant cells in the TME, and their functions and secretions can determine tumor progression. The education of macrophages to M2 polarization can accelerate cancer progression, and therefore, the re-education and reprogramming of these cells is promising. Moreover, macrophages can cause inflammation in aggravating pathological events, including cardiovascular diseases, diabetes, and neurological disorders. The natural products are pleiotropic and broad-spectrum functional compounds that have been deployed as ideal alternatives to conventional drugs in the treatment of cancer. The biological and cellular interactions in the TME can be regulated by natural products, and for this purpose, they enhance the M1 polarization of macrophages, and in addition to inhibiting proliferation and invasion, they impair the chemoresistance. Moreover, since macrophages and changes in the molecular pathways in these cells can cause inflammation, the natural products impair the pro-inflammatory function of macrophages to prevent the pathogenesis and progression of diseases. Even a reduction in macrophage-mediated inflammation can prevent organ fibrosis. Therefore, natural product-mediated macrophage targeting can alleviate both cancerous and non-cancerous diseases.
Substituted benzoyl urea compounds, preparation methods and pharmaceutical uses thereof are disclosed. The compounds are shown by general structure formula (I), wherein R 1 , R 2  and R 3  are defined as those in the description. The compounds can be used as small molecule inhibitors of Cyclophilin A (CypA). CypA is a kind of protein with peptidyl-prolyl  cis-trans  isomerase (PPIase) activity, involved in protein folding, assembly and transportation in vivo. CypA takes part in diverse biological processes, such as autoimmunity inhibition, HIV-1 invasive infection, and so on. Therefore, the compounds of the present application are promising to be developed into novel immunosuppressants or anti-HIV-1 drugs.
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic with good spreadability on the skin, adequate covering power and natural finish feeling compatible with each other, excellent in makeup sustainability as well by including colored mica titanium having a specific particle size. SOLUTION: This makeup cosmetic is obtained by including pref. 0.1-10 wt.% of colored mica titanium 1-15 μm in average particle size (made by coating the surface of mica, sericite, synthetic mica or the like with red iron oxide, yellow iron oxide, black iron oxide, chromium oxide, ultramarine, tar-based coloring matter, natural coloring matter or the like) which is afforded, for example, by coating the surface of commercially available mica titanium with the above colorant followed by e.g. grinding with an air jet collision-type grinder such as a jet mill and then classification. This makeup cosmetic is esp. pref. a foundation because of tending to exhibit the effect of compatibility of adequate covering power with natural finish feeling.
New pharmaceutical compsns. contain 1,2-diphenyl-4-(2-phenylthieothyl)-pyrazolidine-3,5-dione (I) or its salts with bases and are in suitable unit doses for administration of a daily dose of =1g. They are used for treatment of cardiovascular troubles, esp. the treatment of thrombotic troubles by inhibiting the aggregation of thrombocytes (blood platelets). (I) is pref. administered orally in unit doses of 50-200mg. as tablets, capsules or dragees to give daily doses of 2, pref. 0.25-1g. for a 75 kg. adult, but may also be administered by rectal or parenteral routes.
Devices and methods for radioactive embolization for cancer cell therapy in vivo. In a preferred embodiment, the radioactive microspheres are formed of a resin, wherein the alpha emitting isotope is used for tumoricidal purposes. When the alpha emitter decays, the alpha decaying daughter is captured by the resin. In further embodiments, the device comprises at least two isotopes; wherein the first isotope is used for therapeutic purposes and the second isotope is used for dosimetric purposes. The second isotope is a positron emitter for PET-based dosimetry. In a preferred embodiment, the radiation absorbed dose after treatment is determined using the present invention to allow for the simultaneous delivery of treatment and therapeutic efficacy to a cancer patient.
BACKGROUND: Minimally invasive surgery (MIS) for spontaneous supratentorial intracerebral haemorrhage (ICH) is controversial but may be beneficial if end-of-treatment (EOT) haematoma volume is reduced to ≤15 mL. We explored whether MRI findings of cerebral small vessel disease (CSVD) modify the effect of MIS on long-term outcomes.
METHODS: Prespecified blinded subgroup analysis of 288 subjects with qualified imaging sequences from the phase 3 Minimally Invasive Surgery Plus Alteplase for Intracerebral Haemorrhage Evacuation (MISTIE) trial. We tested for heterogeneity in the effects of MIS and MIS+EOT volume ≤15 mL on the trial's primary outcome of good versus poor function at 1 year by the presence of single CSVD features and CSVD scores using multivariable models.
RESULTS: Of 499 patients enrolled in MISTIE III, 288 patients had MRI, 149 (51.7%) randomised to MIS and 139 (48.3%) to standard medical care (SMC). Median (IQR) ICH volume was 42 (30-53) mL. In the full MRI cohort, there was no statistically significant heterogeneity in the effects of MIS versus SMC on 1-year outcomes by any specific CSVD feature or by CSVD scores (all Pinteraction >0.05). In 94 MIS patients with EOT ICH volume ≤15 mL, significant reduction in odds of poor outcome was found with cerebral amyloid angiopathy score <2 (OR, 0.14 (0.05-0.42); Pinteraction=0.006), absence of lacunes (OR, 0.37 (0.18-0.80); Pinteraction=0.02) and absence of severe white matter hyperintensities (WMHs) (OR, 0.22 (0.08-0.58); Pinteraction=0.03).
CONCLUSIONS: Following successful haematoma reduction by MIS, we found significantly lower odds of poor functional outcome with lower total burden of CSVD in addition to absence of lacunes and severe WMHs. CSVD features may have utility for prognostication and patient selection in clinical trials of MIS.
The present invention proposes a design to incorporate medicaments in the capsule shells (body and cap). Medicaments in the cap and body of the capsules may be different. Other medicaments in the form of granules, beads etc. can be filled in the capsules, which may contain medicaments capsule shell. Thus, the same capsule may contain medicaments in the core matrix and in the shell. The key advantage of incorporation of drug in the shell is to obtain a desired rate of release of the medicament, mainly for potent drugs. Other advantage is to produce a combination drug delivery system. The concept can be used for the hard gelatin, hard non-gelatin, soft gelatin and soft non-gelatin capsules. The type of medicaments can be from any class, but should be low-dose medicaments. The medicament has to be stable in capsule shell during manufacture and during appropriate storage conditions for the capsules.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiosurgery. Performing multiple blind laser myocardial revascularization. For this purpose, laser radiation with wave length 1060 nm, average power 3–6 Wt, with pulse 60 ms and pause of 40 ms, with speed of light guide 8–10 mm/s is used. Laser channels are made within healthy myocardial tissues along the perimeter of scarring of visible myocardial damage at distance of 5.0 to 10.0 mm from this zone. Number of channels is 10 to 30. Alloplant implantation is performed by multiple injections into the myocardium bypassing the laser channels within the healthy myocardial tissues along the perimeter of the zone located at distance of 5.0–10.0 mm from the produced laser channels. Number of alloplant injections makes 5–15. Total injection amount of alloplant for this number of injections is 5–10 ml.EFFECT: method enables achieving a high therapeutic effect, reducing intraoperative injuries, eliminating myocardial ischemia.3 cl, 3 ex
PURPOSE:A fibrinolysis promotor, containing an adenosine derivative or an acid addition salt thereof as an active constituent, having improved fibrinolytic promoting action even by the oral administration, preparable easily, useful for treating thrombus or embolism, and easily storable. CONSTITUTION:A fibrinolysis promotor, containing an adenosine derivative of the formula (R<1> is lower dialkylamino, lower alkoxyl or group of -NHR<2>; R<2> is lower halogenoalkyl, lower aminoalkyl, lower hydroxyalkyl or lower formylalkyl, etc.) or an acid addition salt thereof as an active constituent, and orally administrable by mixing with a suitable pharmaceutical carrier. A binder, e.g. a syrup, excipient, e.g. lactose, lubricant, e.g. magnesium stearate, may be cited as the pharmaceutical carrier. The dosage form thereof is a tablet, pill or solution, etc. The daily dose thereof is suitable 5mug-300mg/kg.
The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
Public Health Emergencies (PHE) have had repercussions on health systems on a global scale, and timely access to new health technologies is a challenge for health policy. The national regulatory authorities (NRA) play a key role in the evaluation and regulation of these technologies. The present study aims to analyze the main strategies and regulatory instruments used to deal with the challenges of regulating new technologies necessary for the health system's effective response during a PHE. This research, based on WHO and Brazilian NRA norms and documents, considered dimensions related to strategies for strengthening regulatory activities and regulatory instruments used to accelerate access to technologies, especially during PHEs. International cooperation between the NRA and the WHO were important strategies for strengthening the NRA, with emphasis on the use of reliance, regionalization, accelerated assessments, and work/information sharing, as well as the processes of regulatory harmonization and convergence. In addition to the use of existing regulatory instruments, efforts were also identified in order to implement new ones.
The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
he present invention describes a pharmaceutical dosage form for the delivery of organic nitrates to patients. The form is based on te use of a semi-permeable membrane (2) surrounding a tablet (1) that comprises a combination of one or more organic nitrates and excipients. The membrane (2) defines the rate of water entering the tablet (1). The osmotic pressure that develops, forces the tablet's contents out through an orifice (5) in the membrane, in a specific and controlled rate, independentlyof the conditions of the gastro-intestinal tract. A quantity of the organic nitrates may also be released immediately after the administration of the dosage form, from a layer (3) placed on top of the semi-permeable membrane (2). Thus, the organic nitrates are delivered to the body according to the desired manner, in order to achieve the optimum therapeutic effect. Finally, there may exist an external protective layer (4) providing protection, improved stability and shelf life to the dosage form, as well as easiness in swallowing to the patient.
Drug-carrying nanoparticles can be recognized and captured by macrophages and cleared away by the immune system, resulting in reduced drug efficacy and representing the main drawbacks. Biomimetic nanoparticles, which are coated with cell membranes from natural resources, have been applied to address this problem. This type of nanoparticle maintains some specific biological activities, allowing them to carry drugs reaching designated tissues effectively and have a longer time in circulation. This review article aims to summarize recent progress on biomimetic nanoparticles based on cell membranes. In this paper, we have introduced the classification of biomimetic nanoparticles, their preparation and characterization, and their applications in inflammatory diseases and malignant tumors. We have also analyzed the shortcomings and prospects of this technology, hoping to provide some clues for basic researchers and clinicians engaged in this field.